Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program

Bibliographic Details
Main Authors: Adenis, Antoine, de la Fouchardiere, Christelle, Paule, Bernard, Burtin, Pascal, Tougeron, David, Wallet, Jennifer, Dourthe, Louis-Marie, Etienne, Pierre-Luc, Mineur, Laurent, Clisant, Stéphanie, Phelip, Jean-Marc, Kramar, Andrew, Andre, Thierry
Format: Online
Language:English
Published: BioMed Central 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936193/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936193/

Similar Items